Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC. Foresee will receive a 10 million USD upfront payment, potential milestones of up to 584.5 million USD, single-digit royalties and retains a 19% equity in Primevera, ensuring...
Hence then, the article about foresee pharmaceuticals announces global licensing agreement for mmp 12 inhibitors with primevera therapeutics llc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC )
Also on site :
- OpenAI to acquire the team behind executive coaching AI tool Convogo
- Suspected Oreshnik missile strike in western Ukraine (VIDEO)
- MI-W vs RCB-W Dream11 Prediction, Dream11 Playing XI, Today Match 1, WPL 2026